Revolution Medicines (NASDAQ:RVMDW – Get Free Report) is anticipated to release its results after the market closes on Wednesday, August 5th. Analysts expect Revolution Medicines to post earnings of ($2.0426) per share and revenue of $1.7730 million for the quarter.
Revolution Medicines Stock Down 4.5%
Shares of RVMDW opened at $9.44 on Friday. The stock has a 50-day moving average of $7.86 and a two-hundred day moving average of $4.66. Revolution Medicines has a one year low of $0.16 and a one year high of $10.12.
Revolution Medicines Company Profile
Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.
Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.
Featured Stories
- Five stocks we like better than Revolution Medicines
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
